Usefulness of the octreotide test in Japanese patients for predicting the presence/absence of somatostatin receptor 2 expression in insulinomas

• Nakamura Akinobu

  Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

• Mitsuhashi Tomoko

  Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan

• Takano Yoshinari

  Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

• Miyoshi Hideaki

  Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

• Kameda Hiraku

  Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

• Nomoto Hiroshi

  Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

• Nagai So

  Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

• Hatanaka Yutaka

  Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan

• Shimizu Chikara

  Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan

• Terauchi Yasuo

  Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan

• Atsumi Tatsuya

  Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Abstract

We investigated the relationship between the results of the octreotide test and somatostatin receptor (SSTR) 2 expression in insulinoma patients, to evaluate the usefulness of this test for predicting SSTR2 expression in insulinomas in Japanese patients. Five females and one male were included in the study. All patients underwent the octreotide test before the surgery carried out to resect the tumor, and histopathological examination of the resected tumor was performed by a single experienced pathologist. SSTR2 expression was evaluated by the SSTR2 immunohistochemistry scoring system. Insulinoma was clinically diagnosed and surgically resected in all six patients. In the octreotide test, suppression of insulin secretion was sufficient after loading in patients 1-4 and 6. In patient 5, however, the suppression of insulin secretion was insufficient, which resulted in severe hypoglycemia with endogenous relative hyperinsulinemia after the octreotide loading. The histopathological findings revealed SSTR2 expression in the insulinomas of patients 1-4 and 6, but not in the insulinoma of patient 5. In conclusion, improvement of hyperinsulinemic hypoglycemia by octreotide in Japanese insulinoma patients was associated with SSTR2 expression in the tumor. Our results suggest that the octreotide test could be useful for predicting SSTR2 expression in the tumor.

Journal

• Endocrine Journal

  Endocrine Journal 63 (2), 135-142, 2016

  The Japan Endocrine Society

Keywords

• Insulinoma
• Octreotide
• Somatostatin receptor

Details

• CRID: 1390001206303179008
• NII Article ID: 130005127186
• DOI: 10.1507/endocrj.ej15-0371
• ISSN: 13484540
• ISSN: 09188959
• HANDLE: 2115/68409
• PubMed: 26567922
• Web Site: https://www.jstage.jst.go.jp/article/endocrj/63/2/63_EJ15-0371/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2017035265
• Text Lang: en
• Data Source:
  • JaLC
  • IRDB
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed